Format

Send to

Choose Destination
Blood. 2019 Jan 17;133(3):193-204. doi: 10.1182/blood-2018-06-856062. Epub 2018 Nov 15.

Cerebral cavernous malformations form an anticoagulant vascular domain in humans and mice.

Author information

1
Department of Medicine, University of California, San Diego, La Jolla, CA.
2
Neurovascular Surgery Program, The University of Chicago, Chicago, IL.
3
Department of Molecular Medicine, Scripps Research Institute, La Jolla, CA.
4
Department of Life, Health, and Chemical Sciences, Biomedical Research Network, The Open University, Milton Keynes, United Kingdom; and.
5
Coagulation Biology Laboratory, Oklahoma Medical Research Foundation, Oklahoma City, OK.

Abstract

Cerebral cavernous malformations (CCMs) are common brain vascular dysplasias that are prone to acute and chronic hemorrhage with significant clinical sequelae. The pathogenesis of recurrent bleeding in CCM is incompletely understood. Here, we show that central nervous system hemorrhage in CCMs is associated with locally elevated expression of the anticoagulant endothelial receptors thrombomodulin (TM) and endothelial protein C receptor (EPCR). TM levels are increased in human CCM lesions, as well as in the plasma of patients with CCMs. In mice, endothelial-specific genetic inactivation of Krit1 (Krit1 ECKO ) or Pdcd10 (Pdcd10 ECKO ), which cause CCM formation, results in increased levels of vascular TM and EPCR, as well as in enhanced generation of activated protein C (APC) on endothelial cells. Increased TM expression is due to upregulation of transcription factors KLF2 and KLF4 consequent to the loss of KRIT1 or PDCD10. Increased TM expression contributes to CCM hemorrhage, because genetic inactivation of 1 or 2 copies of the Thbd gene decreases brain hemorrhage in Pdcd10 ECKO mice. Moreover, administration of blocking antibodies against TM and EPCR significantly reduced CCM hemorrhage in Pdcd10 ECKO mice. Thus, a local increase in the endothelial cofactors that generate anticoagulant APC can contribute to bleeding in CCMs, and plasma soluble TM may represent a biomarker for hemorrhagic risk in CCMs.

PMID:
30442679
PMCID:
PMC6337879
[Available on 2020-01-17]
DOI:
10.1182/blood-2018-06-856062

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center